Living Tissue Implants Platform

About PrintBio

PrintBio is a private, US-based biotech firm founded in 2021, operating at the intersection of synthetic biology, regenerative medicine, and advanced manufacturing. The company has developed a proprietary 3D-bioprinting platform initially applied to create its first commercial products: programmable, bioresorbable surgical meshes. Led by a seasoned biotech entrepreneur and surgeon, Dr. Kevin Slawin, PrintBio aims to evolve from surgical mesh into the broader field of on-demand, living tissue and organ implants. Its strategy combines near-term revenue generation from surgical products with a long-term vision for disruptive regenerative therapies.

Therapeutic Areas